However, these programs, well-studied in CD8+ T cells (27, 28), remain less understood in tumor-associated NK cells, including CRC, highlighting the need for detailed investigations into tumor-associated NK cell features that will help design novel combination treatments incorporating NK-based immunotherapies. This evidence concerns the gene CD8A and neoplasm.